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Abstract
Narcolepsy is a chronic, disabling sleep disorder with a significant diagnostic
delay. Nowadays, treatment is focused on managing symptoms that impacts patient’s
life, such as at workplace, social events or even at school, but not aimed cure the
disease. However, we have pharmacological treatments that effectively help control
the main symptoms (excessive daytime sleepiness, cataplexy, fragmentation of noc-
turnal sleep, sleep paralysis and hypnagogic and hypnopompic hallucinations). On
the other hand, pharmacological treatment must be individualised as there are great
variations in severity, order of appearance symptoms and development of the disease.
We intend to expose the different symptomatic treatments recommended by clinical
guidelines and the clinical management from a practical point of view. Future treat-
ments include therapies based on the replacement of hypocretin or the administration
of agonist receptors. Other techniques such as hypothalamic stem cell transplanta-
tion, gene replacement therapy or immunotherapy are also being investigated.
Keywords: narcolepsy, sleep, cataplexy, pharmacotherapy, pharmacology,
sleepiness
1. Introduction
Narcolepsy is a chronic and disabling disease, which, according to the Interna-
tional Classification of Sleep Disorders (ICSD-3), considered to be hypersomnias of
central origin [1]. Narcolepsy presents with a variable combination of sleep–wake
symtoms and motor, psychiatric, emotional, cognitive, metabolic and autonomic
disturbances that reflect the hypothalamic origin of the disorder.
The leading symptoms are:
1.Excessive daytime sleepiness (EDS), which can also manifest with sleep
attacks, involuntary napping, automatic behaviours, difficulty sustaining
attention and memory disturbances.
2.Cataplexy, briefs episodes of bilateral loss of muscle tone triggered by sudden
emotions in the presence of a normal state of consciousness. Often is partial,
rarely complete with falls.
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Other sleep–wake symptoms are fatigue, sleep paralysis, hypnagogic and hyp-
nopompic hallucinations, nightmares, lucid dreams, enacted dreams, disrupted
night-time sleep, restless legs syndrome or parasomnias.
The current International Classification of Sleep Disorders (ICSD-3) defines two
types of narcolepsy:
a. Narcolepsy type 1 (NT1): EDS for > 3 months in association with either CSF
orexin levels < 110 pg./ml or cataplexy and a mean sleep latency < 8 minutes
on the multiple sleep latency test (MSLT) and at least two sleep onset REM
periods (SOREMPs) during MSLT y/o night-time polysomnography.
b. Narcolepsy type 2 (NT2): EDS for > 3 months in the absence of cataplexy but
with a mean sleep latency on the MSLT < 8 minutes and at least two
SOREMPs on the MSLT y/o night-time polysomnography, as well as CSF
orexin levels > 110 pg./ml (or not measured).
If cataplexy develops over time or CSF orexin levels decrease to < 110 pg./ml,
the diagnosis of NT2 must be change to NT1.
The main symptoms of NT1 are related to hypocretin/orexin (ORX) deficiency,
due to the selective destruction, likely autoimmune in origin, of ORX-producing
hypothalamic neurons. Likewise, hypocretin deficiency reduces the excitatory sig-
nal of the neurons responsible for the synthesis of neurotransmitters that promote
wakefulness, such as noradrenaline (NA), dopamine (DA), serotonin (5-HT) and
histamine.
Genetically, approximately 98% of patients with NT1 carry the HLA class II
allele DQB1*06:02; this allele is present in 50% of patients with NT2 and only
12–30% of the general population [2]. So far, no specific antibodies against ORX
neurons have been detected. This could be due either to their location in a restricted
area where there is a small number of damaged antibodies, or because the activation
of specific T cells is negligible.
There is a clear variability in the evolution of the disease over time. On one hand,
it is important to note that when a patient develops symptoms, the hypocretinergic
neurons may already present irreversible damage; on the other hand, on average,
there is a diagnostic delay of 10 years from the onset of symptoms. For this reason,
it is still not possible to establish a concrete and extrapolable pattern. Some patients
observed with severe narcolepsy and cataplexy show full symptomatology in the
first days of the disease, while others develop a progressive course with excessive
daytime sleepiness (EDS) as the initial symptom and followed by cataplexy after
months or years of evolution.
Different hypotheses have been postulated regarding the pathophysiology of
cataplexy. On one hand, there is a direct relationship between the brain areas
responsible for inhibition of muscle tone in REM sleep and hypocretinergic neurons.
The loss of these neurons would cause dissociated REM sleep (the atonia of the REM
phase would appear during wakefulness) manifesting itself clinically as cataplexy or
sleep paralysis [3]. Likewise, it has been proposed that hypocretin deficiency would
facilitate sleep–wake transitions more frequently due to the instability of wake–
sleep regulation mechanisms.
Pharmacotherapy in the treatment of narcolepsy is currently aimed at controlling
the principal symptoms: EDS, cataplexy, sleep fragmentation, sleep paralysis and
hypnagogic and hypnopompic hallucinations, but are not intended to cure the dis-
ease. However, the treatment does manage to significantly improve quality of life.
The following is a detailed breakdown of the different existing treatments and
the promising future lines that are being developed for the treatment of Narcolepsy.
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2. Existing lines of therapy
As we have already mentioned, current therapies are aimed at the symptomatic
treatment of narcolepsy. One key point to take into account is the high degree of
inter-individual variability in the clinical presentation of the disease, in terms of the
different clinical evolution over the years, and the therapeutic response and possible
side effects related to the different treatments.
The first approach should therefore focus on the adoption of non-
pharmacological measures, with programmed short-duration daytime naps being
one of the most prominent.
Establishment of rigid schedules for waking up and going to bed, attempting to
avoid transgressions or sleep deprivation, should be recommended. Like other
patients with sleep disorders, avoiding excessive caffeine or alcohol consumption
should be recommended. Last, but not least, it is helpful to orient the patient from
the point of view of work, providing suggestions as to the jobs that are most
advisable and less advisable for patients with narcolepsy. In addition, they should be
informed of associations or support groups at the national and international level.
Regarding pharmacological therapy, the different existing lines of therapy can
be classified according to their mode of action or according to the type of symp-
tomatology that they are intended to treat (daytime sleepiness, cataplexy, sleep
fragmentation, etc.).
2.1 Recommended treatments for excessive daytime sleepiness (EDS)
1.Modafinil: inhibits the dopamine transporter, facilitating an increase in its
concentration, although its mechanism of action is still unclear. Approved by
the FDA and EMA. Armodafinil is also FDA approved and the usual doses for
adults range from 100 to 250 mg.
Dosage: in tablets of 100–400 mg orally. Initially, treatment is started with
100 mg, which can be divided into two intakes of 50 mg at least 2 hours apart.
The dose should later be increased depending on the degree of drowsiness,
considering the dose-dependent occurrence of side effects.
Pharmacokinetics: the absorption of modafinil is fast, with a maximum plasma
concentration of about 2 to 4 h. The effective elimination half-life of modafinil
after multiple doses is approximately 15 h. The main route of excretion is via
the liver and part of its metabolites via the kidneys. Patients with severe
hepatic impairment should be treated with lower doses. Reversible inhibition
of the cytochrome P450 enzyme CYP2C19, as well as CYP3A4, CYP1A2 and
CYP2B633 has been observed. Coadministration of modafinil with diazepam,
phenytoin and propranolol, which are eliminated via the CYP2C19 enzyme,
may increase their levels. It is recommended that alternative methods of
contraception be considered during treatment with modafinil and one month
after the end of the treatment.
Safety and adverse events: generally well tolerated and the most common
adverse events were headache (13%), nervousness (8%) and nausea (5%).
Treatment-related cardiovascular events were infrequent, including
palpitations (1.5%), hypertension (1%) and tachycardia (1%). Studies with
modafinil have shown a potential for dependence, so the possibility of
dependence with long-term use cannot be completely ruled out. It is also
recommended that an ECG be performed on all patients prior to the start of
treatment.
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The combination of modafinil with connexin-30 inhibitors is under
development (discussed later in the chapter).
2.Methylphenidate: blocks the reuptake of noradrenaline and dopamine
(inhibiting the transporters of these neurotransmitters at the presynaptic level)
increasing the concentration of dopamine and noradrenaline in the synaptic
cleft. Broadly speaking, this generates its stimulant effect within the central
nervous system (CNS), primarily in the prefrontal cortex. It is also a weak
agonist at the 5-HT1A receptor, which is an additional mechanism that
contributes to increased dopamine levels. Before starting any treatment with
stimulants, it is advisable to perform at least an electrocardiogram to rule out
possible cardiac arrhythmias [4]. Due to the risk of serious side effects, avoiding
use with patients with structural heart abnormalities is recommended.
Dosage: doses are administered orally and range between 10 and 60 mg and
should not exceed 72 mg. Immediate and extended release are available.
Adverse effects: insomnia and nervousness are the most frequent events,
although other effects related to the CNS (dizziness, headache, tics,
akathisia), gastrointestinal (nausea/vomiting, dry mouth, decreased appetite,
weight loss, abdominal pain) and cardiovascular system (tachycardia and
palpitations) have also been reported. Methylphenidate is FDA approved for
the treatment of attention deficit hyperactivity disorder (ADHD) in children
and adults and as a second-line treatment for narcolepsy in adults.
3.Pitolisant: histamine H3-receptor antagonist-inverse agonist (to be developed
later).
4.Amphetamines or dextroamphetamine: the main action is through increases in
synaptic concentrations of monoamine neurotransmitters, thus indirectly
enhancing noradrenergic and dopaminergic neurotransmission in the CNS.
Catecholaminergic signalling is the primary mediator of efficacy in narcolepsy.
This same pathway is also responsible for the major side effects, as well as its
potential for abuse. It should be considered that it is a drug with very limited
use, because there is a difficult balance between achieving correct therapeutic
efficacy and an acceptable control of side effects.
Dosage: doses between 5 and 30 mg orally, twice a day, or 20 mg in a sustained
release formulation twice a day are usually used.
Adverse effects: decreased appetite, nausea, vomiting, insomnia, headache,
increased blood pressure and heart rate, etc.
Safety: has a high potential for abuse, can cause psychosis and manic episodes.
2.2 Recommended treatments for cataplexy and symptoms resulting from
dysregulation of REM sleep
1.Sodium oxybate (Xyrem®): this is the sodium salt of gamma-hydroxybutyrate
(GHB). GHB is synthesised in neurons throughout the CNS and is an active
metabolite of gamma-aminobutyric acid (GABA). It inhibits noradrenergic
neurons in the locus coeruleus during sleep, with a rebound effect of these
neurons during the day thus promoting wakefulness, although its mechanism
of action remains unclear. One of the hypotheses about the mechanism of
action on the control of EDS and cataplexy postulates that it could be mediated
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through GABA-B agonist actions on dopaminergic, noradrenergic, as well as
thalamocortical neurons. In 1998, the FDA granted permission to test oxybate
as an orphan drug for narcolepsy. In 2002 it developed a distribution program
through hospital pharmacies only. And in Europe, it is available under
restricted prescription and special situation. It also has a risk management and
pharmacovigilance program.
Dosage: it is an oral solution (500 mg/ml). The recommended initial dose is
4.5 g/night (divided into 2 doses, each of 2.25 grams) spaced at least 2.5–
4 hours apart before the new dose, so that most of the drug has been
eliminated when the patient wakes up. Up to a maximum of 9 g/day (7 g/day
in children <12 years).
Pharmacokinetics: it is rapidly absorbed with a maximum plasma
concentration (tmax) of 1.5–2 h. Less than 5% of the unaltered drug appears in
the urine 6–8 h after dosing. No active metabolites. Also does not induce
cytochrome P450 enzymes. In patients with cirrhosis of the liver, a lower dose
should be started because a doubling of the area under the curve, reduced oral
clearance and prolonged elimination half-life have been observed.
Safety: the most frequent adverse effects were: headache (11.6%),
nasopharyngitis (6.4%), dizziness (5.2%), weight loss (5.2%), nausea (5.1%),
urinary incontinence in (2.4%) and sleepwalking in (3.1%). Serious adverse
events included depression, angina, inguinal hernia, psychosis or attempted
suicide. In addition, the European Medicines Agency (EMA) recommends
assessing the risk/benefit in patients with obstructive sleep apnoea syndrome
(OSA), especially in doses higher than 6 g/night. On the other hand, it is
important to control daily salt intake in patients with heart failure,
hypertension or renal failure because the molecule has a high salt content. It
also must be taken under consideration the potential for abuse, before being
administered, the patient’s medical history should be reviewed.
Recently, a multi-centre, randomised, placebo-controlled trial involving
children and adolescents with narcolepsy with cataplexy was developed
examining efficacy and safety. Based on this study, the FDA approved the use
of sodium oxybate in paediatric patients with narcolepsy beginning at seven
years of age.
There are now new therapeutic lines with controlled-release GHB (see below).
2.Pitolisant: histamine H3-receptor inverse antagonist–agonist (to be developed
later).
3.Venlafaxine and Duloxetine: are dual serotonin and noradrenaline reuptake
inhibitors. These are the most used antidepressants to control cataplexy. This
recommendation lacks clinical evidence of efficacy and is based solely on
expert opinions.
Dosage: initially 37.5 mg, sometimes requiring higher doses (75–300 mg). The
extended-release form is preferable.
Safety: It can be administered to children and is not recommended for
pregnant women.
4.Fluoxetine and Citalopram: are selective serotonin reuptake inhibitors (SSRIs).
A crossover study comparing clomipramine and fluvoxamine showed that
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SSRIs improved cataplexy, but were less active than the antidepressant.
Studies have been carried out with femoxetine, zimelidine and escitalopram
showing a clear anticataplectic effect and good tolerance.
5.Reboxetine: dopamine and noradrenaline reuptake inhibitor (discussed
below).
6.Monoamine oxidase inhibitors (MAOIs): act by inhibiting the enzyme
monoamine oxidase by increasing the availability of monoamine
neurotransmitters. A suppression of REM sleep has been observed as the main
effect. Phenelzine has been used successfully in seven patients with resistant
narcolepsy, with persistent efficacy after 1 year of treatment. In addition, there
have been two placebo-controlled studies with selegiline (MAO-B inhibitors)
at doses of 20–40 mg which demonstrated a significant reduction in the
frequency of cataplexy. With MAO-A inhibitors such as brofaromine,
significant results were also obtained, reducing cataplexy with no significant
side effects. However, they are rarely used in clinical practice due to their
adverse effects (weight gain, orthostatic hypotension, irritability, sweating,
dry mouth, etc.)
7.Tricyclic antidepressants (TCAs): are non-specific monoamine reuptake
inhibitors that increase the availability of serotonin, noradrenaline and
dopamine. Some also have anticholinergic effects that may affect the anti-
cataplegic properties.
Dosage: between 10 and 150 mg, generally lower doses than those used as an
antidepressant are needed to be effective in controlling cataplexy and its
effects are very fast (only a few days) compared to the effects as an
antidepressant. Several antidepressants have been tried, but clomipramine has
been the most commonly used TCA.
Safety: if the antidepressant is abruptly discontinued, an elevated risk of
rebound cataplexy or “status cataplecticus” has been observed.
It should be noted that the Class I evidence for Narcolepsy with cataplexy (NT1)
and without cataplexy (NT2) was obtained for the previously described
psychostimulant drugs and for sodium oxybate. Oxybate therefore remains the
first-line treatment of choice in NT1, especially for the control of cataplexy,
although as we will see below, pitolisant demonstrated efficacy similar to oxybate in
patients with NT1 in a recent randomised placebo-controlled clinical trial.
2.3 Treatments currently being developed
1.Pitolisant (Wakix®): as we have explained previously, this is an inverse
agonist of the histamine H3 receptor (competitive H3R antagonist) that acts at
presynaptic level activating histaminergic neurons (it blocks the inhibitory
effect of histamine on the release of endogenous histamine and improves the
release in the entire central nervous system) favouring wakefulness and also
with an additive anticataplectic effect. It was designated an Orphan Medicinal
Product by the European Medicines Agency in 2007 and confirmed again in
2016 [5]. It was also granted orphan drug status by the FDA in 2010. It has
been approved by the European Medicines Agency (EMA) in 2016 and by the
FDA in 2019 for NT1 and NT2.
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Dosage: single morning dose (9–36 mg/day) orally. 4.5 mg and 18 mg tablets.
In Spain it is dispensed in hospital pharmacies. The guideline approved in
Europe is as follows:
1st week: the starting dose is 9 mg divided into two 4.5 mg tablets to be
administered at the same time in the morning.
2nd week: increase to one 18 mg tablet or consider decreasing the dose to
4.5 mg.
3rd week: the recommended dose is 36 mg, consisting of two 18 mg tablets.
Pharmacokinetics: it is rapidly absorbed, with a maximum plasma
concentration (tmax) of 3.5 h and an elimination half-life (t1/2) of
approximately 10–12 hours. It is metabolised through cytochrome p450
(CYP3A4) and (CYP2D6) and eliminated in urine as inactive metabolites and
25% of the dose is excreted through exhaled air.
Safety: it has a good tolerance profile even after one year of follow-up, as well
as good control of cataplexy. It should be noted that Pitolisant would be of
special interest to patients with cardiovascular comorbidities. It has very low
abuse potential: a study in comparison to Phentermine and a placebo in
patients with a history of recreational polydrug use indicated that Pitolisant, at
therapeutic and supratherapeutic doses, has a similar abuse risk to the placebo.
The maximum recommended dose in moderate–severe hepatic or renal
impairment is 17.8 mg and it is contraindicated in end-stage kidney disease or
severe liver disease. In women of childbearing age, it is recommended that a
non-hormonal method of contraception be used during treatment and 21 days
after stopping treatment. Antidepressants and antihistamines (which cross the
blood–brain barrier) may reduce the efficacy of Pitolisant and special caution
should be exercised because of the narrow therapeutic margin when using
certain treatments such as immunosuppressants.
In a clinical trial, it was observed that pitolisant did not modify the
pharmacokinetic profiles of oxybate or modafinil, and oxybate showed no
relevant effect on pitolisant. However, a reduction in exposure was observed
with modafinil, although no dose adjustment was necessary.
Side effects: in order of frequency were insomnia (8.4%), headache (7.7%),
nausea (4.8%), anxiety (2.1%), irritability (1.8%), dizziness, etc. The most
serious adverse effects: abnormal weight loss and miscarriage (only 0.09%).
In the HAROSA I and II trials in patients with Obstructive Sleep Apnoea
Syndrome and cardiovascular comorbidities, no changes in systolic and
diastolic blood pressure and heart rate were observed [6] compared to a
placebo. Supratherapeutic doses between 108 and 216 mg produce an increase
in the QTc interval (10–13 ms), so caution should be exercised with those
drugs that prolong QT. No ECG is required before starting treatment.
Based on our clinical experience in the Sleep Unit of the Hospital General
Universitario de Castellón, below we provide the results of patients who
followed the compassionate-use program prior to commercialization, to
initiate treatment with pitolisant in 14 adult patients and one patient with
paediatric narcolepsy who did not respond to the treatments available at that
time:
8 patients diagnosed with NT1: request made on the basis of EDS, and/or
persistent cataplexy.
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Resistance or intolerance to available treatments (modafinil, sodium oxybate,
dimethylphenidate… )
3 patients with NT2: two patients with secondary narcolepsy (Steinert’s
myotonic dystrophy, Devic’s neuromyelitis optica) and one patient with
intolerance to modafinil and/or dimethylphenidate.
2 patients with idiopathic hypersomnia: one patient who reported severe
hypersomnia and another patient in whom Modafinil was contraindicated due
to adverse effects.
1 patient with obstructive sleep apnoea syndrome (OSAHS) who presented
residual hypersomnolence without improvement with modafinil.
A 14-year-old boy with narcolepsy without cataplexy, as first line treatment
for excessive daytime sleepiness after having been treated with
methylphenidate.
Currently, all patients with NT2, idiopathic hypersomnia and sleepiness
secondary to (OSA) continue to be treated and the symptoms of EDS have
been corrected.
Of the patients with NT1, 3 continue to be treated and the cataplexy, which
was mild–moderate, has been controlled. The other 5 patients dropped out due
to lack of response because they presented severe cataplexy since being
diagnosed with the disease.
In Ref. to safety and adverse events (AE): 2 patients out of the 15 who
started treatment with pitolisant had conciliation insomnia. One was a patient
with NT2 secondary to neuromyelitis optica, who presented this
symptomatology with a dose of 18 mg, which was resolved by lowering the
dose to 13.5 mg. The second patient presented NT1, in treatment with
sodium oxybate 5.5 grams/night associated with pitolisant 36 mg/day that
reverted when the dose of pitolisant was reduced to 22.5 mg. There was no
other type of AE.
2.Solriamfetol (JZP-110): a selective dopamine and noradrenaline reuptake
inhibitor (with no effect on the release of other monoamines) intended to
improve drowsiness (EDS) in patients with obstructive sleep apnoea or
narcolepsy [7]. In 2019, the FDA approved it for narcolepsy-associated
drowsiness and the EMA is currently reviewing the marketing authorisation
application for this indication. At the moment, experience with Solriamfetol is
limited.
Dose: range 75–150 mg/day of oral administration.
Pharmacokinetics: it is rapidly absorbed, with a maximum plasma
concentration (tmax) of 2 hours and an elimination half-life (t1/2) of
approximately 7 hours. It is minimally metabolised and excreted mainly in
the urine as an unchanged drug. Dose adjustment is recommended in
moderate and severe renal insufficiency (maximum doses 75 and
37.5 mg/day, respectively). It should not be used concomitantly with
monoamine oxidase inhibitors (MAOIs), which should be discontinued
2 weeks in advance.
Adverse events: headache (11.1%), nausea (6.6%) and decreased appetite
(6.8%) and less frequently dry mouth, constipation, anxiety and palpitations.
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It is important to note that it is not necessary to discontinue oral and hormonal
contraception as is recommended for modafinil and pitolisant.
Safety: Abuse potential was assessed in patients with a history of recreational
polydrug use compared to phentermine. In conclusion, they present a similar
or lower risk of abuse than phentermine and have therefore received a
Schedule IV designation in the United States.
Two studies have been conducted: a first 12-week, randomised, double-blind,
placebo-controlled phase IIb trial to evaluate efficacy in adults with
narcolepsy with or without cataplexy. And a similarly designed phase III trial
of 12 weeks duration for the treatment of obstructive sleep apnoea and EDS in
narcolepsy.
3. Summary
In recent years there has been a significant increase in new therapeutic options
such as Pitolisant and Solriamfetol, aimed at developing better control of narcolepsy
symptoms.
Pitolisant is positioned as a first-line drug of choice for the management of
symptoms such as excessive daytime sleepiness and cataplexy, in addition to being
able to be used in both adults and children, and is the only one of the new thera-
peutic lines whose use is considered in paediatric narcolepsy. With regard to the
usual treatments, as we have already mentioned, a clinical trial with sodium oxybate
in the paediatric population has also been published recently.
Solriamfetol would be included in the first line treatment of excessive daytime
sleepiness (EDS) in adults. In addition, the use of both Pitolisant and Solriamfetol
would be advisable as a first-line strategy, in combination with the other
anticataplectic drugs for a better control of cataplexy. Both can be used in combi-
nation for second-line treatment of EDS.
Pharmacological strategy of the European guidelines for the treatment of
narcolepsy [8]:
9
Narcolepsy Treatment: Present and Future
DOI: http://dx.doi.org/10.5772/intechopen.99777
3.1 Therapies under development
1.AXS-12 (Reboxetine): a selective NA reuptake inhibitor with a weak effect on
5-HT reuptake and no effect on DA reuptake. It is a drug initially intended for
the treatment of depression. It is currently in development for the treatment of
cataplexy and EDS associated with narcolepsy. The FDA has designated it as an
orphan drug. Preclinical data have shown a reduction in cataplexy and sleep
attacks in narcoleptic mice (attributed to an effect on NA reuptake inhibition).
Since noradrenaline reuptake inhibitors are very effective for the treatment of
cataplexy, it will probably be used to control cataplexy and become an
alternative for patients who cannot take oxybate and pitolisant. One of the
possible indications could be the treatment of patients with major depressive
disorder and narcolepsy [8].
Pharmacokinetics: Rapidly absorbed after oral administration (tmax)
approximately 2–4 h and eliminated mainly through metabolism by CYP3A4.
Safety: A Phase II, randomised, double-blind, placebo-controlled, crossover
study is underway in participants with narcolepsy with cataplexy and EDS.
Adverse events: dry mouth, hyperhidrosis, constipation and restlessness were
reported in a 2-week pilot study. Post-marketing experience (with indication
for depression) has reported other AEs such as: insomnia, dizziness, dry
mouth, constipation, nausea and hyperhidrosis.
2.THN102 (modafinil/flecainide): this is the association of the inhibitory effect
of astroglial connexins associated with a dopamine reuptake inhibitor,
improving the coupling of astroglial cells, since it is believed that astrocytes
and astroglial connexins are involved in the regulation of sleep and
wakefulness. In the cortex, modafinil would act by increasing the expression of
messenger RNA (mRNA) and the connexin 30 protein, one of the main
astroglial connections. On the other hand, flecainide has an inhibitory effect on
10
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astroglial connexins. In preclinical studies, flecainide enhanced the
procognitive and wakefulness-promoting effects of modafinil in mice and
modafinil/flecainide coadministration decreased the number and duration of
direct transitions to REM sleep in orexin-inactivated mice.
Pharmacokinetics: not specifically reported. Data from mouse models indicate
that flecainide did not affect the pharmacokinetic parameters and
bioavailability of modafinil.
Efficacy: evaluated in a three-way, phase II, double-blind, randomised,
placebo-controlled, crossover trial in 48 adults with narcolepsy with or
without cataplexy for 2 weeks. Participants received modafinil/flecainide 300/
3 mg, modafinil/flecainide 300/27 mg and modafinil 300 mg/placebo in each
of the three periods. Preliminary results indicated no difference in efficacy
between THN102 and modafinil alone. This could be due to an over-
representation of participants with severe narcolepsy who presented a low
response to modafinil.
Safety: no safety data currently available.
The potential role of THN102 in narcolepsy is unclear. The narcolepsy study
was stopped due to lack of efficacy in the phase II study.
3.Divalproex sodium: increases exposure to sodium oxybate, allowing the dose
of sodium oxybate to be decreased. Concomitant use of other central nervous
system (CNS) depressants may intensify the central depressant effects of
sodium oxybate.
4.FT-218: (Controlled-release sodium oxybate): acts on the GABA-B agonist
receptors and uses Micropump technology®, a microparticle platform that can
be used to achieve prolonged or delayed delivery of orally administered small-
molecule drugs. The dosage would therefore be only once a night. The FDA has
currently designated it as an orphan drug.
Dosage: 4.5–6-7.5 or 9 g once a night.
Pharmacokinetics: A Phase III trial evaluating the bioavailability of FT218
compared to immediate-release sodium oxybate (Xyrem®) in healthy
volunteers is currently under development.
Efficacy: of FT218 is being evaluated in another phase III, multi-centre, double-
blind, placebo-controlled REST-ON trial (Randomised study Evaluating the
efficacy and SafeTy of a Once Nightly formulation of sodium oxybate). Adverse
effects are expected to be similar to immediate-release sodium oxybate.
5. JZP-258: is a new low sodium oxybate product (combination of sodium
oxybate, potassium oxybate, calcium oxybate and magnesium oxybate) and
has 92% less sodium. It would therefore be more advisable for use in patients
with hypertension, heart failure or renal failure). In addition, it is tolerated
better because it does not leave an unpleasant taste and does not have as many
gastrointestinal effects as sodium oxybate.
Pharmacokinetics: lower Cmax, longer tmax and similar AUC were obtained
compared to sodium oxybate.
Efficacy: evaluated in a phase III multi-centre, randomised, phase III
withdrawal study.
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Adverse events: reported most frequently were headache (22.4%), nausea
(13.4%) and dizziness (11.4%); treatment-related SAEs were reported in only
two participants. In addition, a 24-week open-label safety study is underway.
6.SUVN-G3031: is an inverse agonist of the histamine 3 receptor (H3R) that is in
phase II development.
Anticataplectic and wakefulness-promoting effects have been observed in
rodents, increasing acetylcholine, histamine, DA and NA levels in the cortex,
but without altering DA levels in the striatum or nucleus accumbens, which
might suggest a lower abuse potential. No adverse effects on ECG parameters,
fertility, embryofoetal development or CNS safety concerns have been
reported in preclinical studies.
7.TAK-925: is a selective agonist of the hypocretin/orexin 2 receptor (ORX2R). It
has demonstrated wakefulness-promoting effects in wild mice and primates. It
also increased wakefulness time and improved wakefulness fragmentation and
cataplexy and attenuated weight gain in ORX/ataxin-3 transgenic mice
without changing food intake. If the results are confirmed, it could be targeted
to treat a wide range of symptoms without causing ORX2R desensitisation.
Pharmacokinetics: A Phase I study with single ascending doses (7–240 mg,
administered as an intravenous infusion over 9 hours) has been conducted in
36 healthy volunteers, evaluating safety, pharmacokinetics and tolerability. In
addition, another placebo-controlled crossover study was carried out in 14
NT1 patients where doses of (5, 11.2 and 44.8 mg, as a 9 h intravenous
infusion) were administered [9]. The exposure was proportional to the dose
over the dose range studied and t1/2 was less than 2 h; PKs were similar in
healthy volunteers and NT1 patients.
Adverse events: increase in blood pressure and HR. Improved mean sleep
latency as determined by the TMW maintenance of wakefulness test in NT1
patients (from 22.4, 37.6, and 40.0 min with TAK-925 5, 11.2, and 44.8 mg,
respectively, compared to 2.9 min with placebo.
8.TAK-994a selective hypocretin/orexin 2 receptor agonist (administered
orally), has been shown to increase wakefulness and reduce cataplexy-like
episodes in mouse models and to improve wakefulness fragmentation in these
models.
4. Future therapies
A.Administration of orexin peptides (ORXR2) as effective stimulants may also
be of interest to decrease EDS in patients with NT2 and idiopathic
hypersomnia and associated conditions with normal CSF ORX levels.
B. Neural transplantation of orexin: Hypocretin-1 does not cross the blood–brain
barrier. In animal models, it has been observed that intraventricular
administration of ORX suppressed narcolepsy symptoms in mice subjected to
ORX/ataxin-3 neuronal ablation. Intrathecal ORX administration via an
implantable pump was also proposed as a therapy for refractory patients with
NT1. Unfortunately, these models have not been developed in humans, so the
development of peptide analogues of hypocretin that cross the blood–brain
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barrier and act centrally via non-invasive routes of administration would be
the most viable future therapy. On the other hand, a non-invasive method
through intranasal administration of ORX, directing the drugs to the brain
along the olfactory and trigeminal neural pathways, could also be of interest as
it has been shown to decrease the amount of REM sleep and REM sleep is more
stable, but no effect has been observedin regard to drowsiness. At present,
intranasal hypocretin is not a viable treatment [10, 11].
C. Transformation of stem cells into orexin neurons: in rats, patches have been
transplanted with posterior hypothalamus cells causing a reduction in
drowsiness. Hypothalamic neurons have been generated in vitro from
embryonic stem cells and pluripotent stem cells. This therapy could therefore
become a final option for very severe and drug-resistant narcoleptic patients.
D.Orexin-based gene therapy: the use of recombinant viruses has been
postulated. Studies have been promising (improving symptoms in
narcoleptics). More studies are needed to establish the safety and efficacy of
the technique, but they could be future therapies.
E. Immune therapy: as mentioned above, by the time a patient is symptomatic,
ORX neurons may already be irreversibly destroyed. A recent article used a
highly sensitive method to detect rare T cell populations and found the
presence of CD4+ T cells that recognised prepro-ORX peptide epitopes in NT1
and that have not been observed in healthy controls. Based on the model of
immune-mediated hypocretinergic neurone destruction, immunotherapy
applied at the onset of the disease to prevent neuronal death was postulated as
a treatment. To date, several studies have been conducted implementing this
methodology in narcoleptics, but the existing data are based on a very small
number of patients, and they are uncontrolled case studies. Some of the
different therapeutic strategies that have been tried include: corticosteroids,
intravenous immunoglobulins (IVIG), plasmapheresis, rituximab, etc. with
variable efficacy, possibly due to the lack of safety if the treatment was applied
at the onset of the disease and not when the situation was already irreversible.
A study has been published of a patient who received treatment with IVIG for
15 days right at the onset of the disease, completely reversing the clinical
symptoms (EDS and cataplexy) and normalising the levels of ORX in CSF,
which were initially undetectable. Regarding new immune-based therapies. A
recent review has been published, presenting several treatments targeting
NT1, including: Natalizumab, Fingolimod, Abatacept, monoclonal antibodies
targeting T or B cells, TNF alpha inhibitors, Anakinra, antigen-specific
therapies or Cyclophosphamide. In another study they propose that for future
trials with immunotherapy, patients should have a specific profile with clear
selection criteria, benefiting above all, those with ongoing inflammatory or
autoimmune processes [12].
5. Conclusion
Recent years have seen a resurgence of new lines of therapy for the treatment of
narcolepsy. These new future prospects predict a promising prognosis in terms of
being able to guarantee a better quality of life for patients with narcolepsy, perhaps
even a possible correction of the hypocretin deficit, completely resolving the symp-
tomatology and achieving complete control of the disease. Future lines of research
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should be based on the discovery of new reliable biomarkers to be able to identify
the patients who best respond to immunomodulators and, of course, on the discov-
ery of the underlying mechanisms related to the destruction of hypocretin-
producing neurons. On the other hand, we have highlighted the lack of clinical trials
in some specific groups, such as pregnant women or the elderly population. In
addition, further trials in patients with common comorbidities such as psychiatric
disorders or cardiovascular risk factors would be of interest.
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